Board-certified rheumatologist Dr. Mahsa Tehrani discusses President Donald Trump’s possible 25% tariff on overseas ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

C an drugs like Ozempic slow down the development of cognitive diseases, such as dementia and Alzheimer’s? According to ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

Two undergraduate medicine students have led a major study examining how cardioprotective glucose-lowering therapies -- medications that lower blood sugar and reduce the risk of heart disease in ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...